parvovirus [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.

As a prototype, parvovirus has been tested as an [[oncolytic virus]] OV from preclinical proof-of-concept up to first-in-human clinical studies. The approval of the first OV in the Western world, T-VEC ([[Imlygic]]), has further spurred the involvement of investigators in Germany in international multicenter studies. With the encouraging developments in funding, commercialization, and regulatory procedures, more German engineering will be translated into OV clinical trials in the near future
((Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm
PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, 
Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM. Virotherapy Research in
Germany: From Engineering to Translation. Hum Gene Ther. 2017 Oct;28(10):800-819.
doi: 10.1089/hum.2017.138. PubMed PMID: 28870120.
)).